Key facts
- Infilbray can cross into the brain, letting it treat worsening balance, coordination, speech, memory and thinking problems in type 3 disease.
- The drug lowers production of fatty substances, unlike Cerezyme, which supplies the missing enzyme in Gaucher disease.
- The FDA warned of serious psychiatric risks, including suicidal thoughts and behavior, and cited digestive problems and mood changes as common side effects.
- Sanofi said Infilbray is under regulatory review for type 3 Gaucher disease in the European Union and Japan.
- Sanofi already sells Cerdelga for type 1 Gaucher disease and Cerezyme for symptoms outside the brain and nervous system in types 1 and 3.
The US FDA on Wednesday approved Sanofi's oral drug venglustat, branded Infilbray, for type 3 Gaucher disease, the first treatment approved for the neurological variant of the rare genetic condition, Reuters reported on November 18, 2026. The disorder causes certain fatty substances to accumulate in organs and tissues.
Infilbray can cross into the brain, allowing it to treat worsening problems with balance, coordination, speech, memory and thinking in type 3 disease. It works by lowering production of the fatty substances, unlike therapies such as Cerezyme, which supply the missing enzyme.
The approval, for adults and children weighing at least 15 kilograms, or about 33 pounds, was based on a late-stage study of 43 patients aged 12 and older whose symptoms outside the brain had been stabilized with enzyme replacement therapy. Patients receiving Infilbray once daily for 52 weeks improved on a combined measure of muscle control, coordination and thinking ability compared with those receiving enzyme replacement therapy every two weeks.
The FDA said the most frequently reported side effects included digestive problems and changes in mood, and warned of serious psychiatric risks, including suicidal thoughts and behavior. It said animal studies identified potential vision clouding in younger patients and adverse effects on fetal development.
Sanofi's portfolio already includes Gaucher therapies: Cerdelga for type 1 and Cerezyme for symptoms outside the brain and nervous system in patients with types 1 and 3. Under CEO Belén Garijo, Sanofi is seeking to reduce its reliance on the asthma drug Dupixent, which is set to lose key patent exclusivity by the early 2030s. Sanofi said Infilbray is under regulatory review for type 3 Gaucher disease in the European Union and Japan.
